Trending Now
ProQR Therapeutics N.V. (NASDAQ: PRQR) Signs Licensing and Research Agreement With...
ProQR Therapeutics N.V. (NASDAQ: PRQR) has announced a worldwide licensing and research agreement with Eli Lilly and Company to discover, produce, and commercial possible...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Longeveron Inc (NASDAQ: LGVN) Executes an Agreement With the United States...
Longeveron Inc (NASDAQ: LGVN) recently announced the execution of a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs....
MAKE IT MODERN
LATEST REVIEWS
Capitalizing on the Generational Washout in Crypto Markets (RIOT, BLQC, COIN,...
After the past week, the cryptocurrency space is now the poster child for this bear market in global risk assets. It has...
MAKE IT MODERN
PERFORMANCE TRAINING
What’s Driving the Energy Trade? (VKIN, CEI, HP, FANG, XEC, SBOW, MTDR, HES)
You may have noticed your price going up at the pump.
That’s not some trick of perception. Energy prices...
Mangoceuticals (NASDAQ: MGRX) Growing Prospects in $30B Men’s Health and Wellness Segment (RLX, CLOV,...
As light shines on the health and wellness of individuals, especially men, and taboos relating to speaking about mental, spiritual, and physical...
Sio Gene Therapies Inc. (NASDAQ: SIOX) Confirms the Dosing of the First Patient with...
Every patient deserves long-lasting and transformative therapies. Throughout its existence, Sio Gene Therapies Inc. (NASDAQ: SIOX) has had one primary focus; to enhance the...
Editas Medicine Inc. (NASDAQ:EDT) Announces Q3 Results And Progress Of The EDIT-101 Development Program
Editas Medicine Inc. (NASDAQ:EDT) has announced its Q3 2020 results and business highlights.
Editas doses first patients with EDIT-101
Cynthia Collins, Editas Medicine's CEO, said that...
MediciNova, Inc. (NASDAQ:MNOV) Presents the results of Phase 2 Trial of MN 166 (ibudilast)...
In collaboration with Dr. Lara Ray, Professor, Department of Psychology at the University of California Los Angeles (UCLA), MediciNova, Inc. (NASDAQ:MNOV) has presented results...
MAKE IT MODERN
